Programme Day 2

Moderators: Hanne Skille (Norway) and Tomas Lindahl (Sweden)

• 09.30 – 10.00: VTE therapy in patients with Cancer, Manuel Monreal, Spain
• 10.00 – 10.15: Platelets promote metastatic dissemination in mouse and human models in vivo and are associated with reduced survival in lung adenocarcinoma patients, Stephanie Hyslop, Australia
• 10.15 – 10.30: The impact of second cancer on the risk of cancer associated venous thromboembolism; a Danish nationwide study, Inger Lise Gade, Denmark

Moderator: Johannes Thaler (Austria)

• 09.30 – 10.00: Non-substitutive treatments in Haemophilia, Michael Makris, United Kingdom
• 10.00 – 10.15: A fully-human bispecific antibody for the treatment of hemophilia A, John Blackwood, United Kingdom
• 10.15 – 10.30: Emicizumab demonstrates long term efficacy and tolerability in a broad population of persons with haemophilia A (PwHA) with or without FVIII inhibitors: pooled data from four HAVEN studies, Michael Callaghan, United States

Moderators: Mike Laffan (United Kingdom) and Sophie Susen (France)

• 09.30 – 10.00: Microparticles, ready for the clinic?, Françoise Dignat-George, France
• 10.00 – 10.15: In Silico Peptide Design: from molecular mechanism to novel therapeutic treatments for inflammatory diseases, Kanin Wichapong, The Netherlands
• 10.15 – 10.30: Targeting CXCL1-deposition on the vessel wall with a tick-derived protein, Ingrid Dijkgraaf, The Netherlands

Moderators: Tassos Petri (United Kingdom) and Thomas Kümler (Denmark)

• 09.30 – 10.00: Protein S – at the centre of haemostatic regulation, Josefin Ahnström, United Kingdom
• 10.00 – 10.15: Characterisation of citrullinated TFPI and truncated TFPI constructs by PAD4 in model and plasma systems, Stella Thomassen, The Netherlands
• 10.15 – 10.30: Molecular, biological and clinical characterization of variants affecting the C-terminal end of antithrombin, Carlos Bravo-Perez, Spain

Moderators: Claire Whyte (United Kingdom) and Marco Heestermans (Germany)

• 14.30 – 14.45: Factor XII proline rich domain is essential for contact activation, Marco Heestermans, Germany
• 14.45 – 15.00: High molecular weight kininogen but not factor XII deficiency protects against acetaminophen-induced hepatotoxicity in mice, Rafal Pawlinski, United States
• 15.00 – 15.15: uPA-mediated plasminogen activation is enhanced by polyphosphate, Claire Whyte, United Kingdom

Moderators: Cédric Duval (United Kingdom) and Eugenia Biguzzi (Italy)

• 14.30 – 14.45: Endothelial cells derived from induced pluripotent stem cells have the potential to model von Willebrand Disease, Matthew Sims, United Kingdom
• 14.45 – 15.00: Acquired Von Willebrand syndrome associated with monoclonal gammopathy, Eugenia Biguzzi, Italy
• 15.00 – 15.15: Determination of prevalence and features of main VWF synonymous variants of the CRMW database, Fanny Lassalle, France

Moderators: Helen Mcpherson (United Kingdom) and Catherine Lemarie (France)

• 14.30 – 14.45: TLR3 promotes venous thrombosis through neutrophil recruitment, Maria Najem, France
• 14.45 – 15.00: CTL-2 is a VWF receptor involved in neutrophil activation, Gaia Zirka, France
• 15.00 – 15.15: DNAse-dependent but NETs-independent pathways of thrombus formation in vivo, Estelle Carminita, France

Moderators: Joanne Dunster (United Kingdom) and Irina Zotova (Russia)

• 14.30 – 14.45: Allelic polymorphism of platelet glycoprotein genes GPIa and GPIIb as a possible predictive marker of response to therapy in patients with primary immune thrombocytopenia, Irina Zotova, Russia
• 14.45 – 15.00: Platelet biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis, Alessandro Ciavarella, Italy
• 15.00 – 15.15: Effect of antiplatelet agents on bacterial induced platelet aggregation, Laurence Camoin-Jau, France

Moderators: Sabine Eichinger (Austria) and Tomas Lindahl (Sweden)

15.45 – 16.10: Immunogenicity of coagulation factors, Jan Voorberg, Sanquin

16.10 – 16.35: Immunogenicity of monoclonal abs with a focus on Emicizumab, Gallia Levy, Roche

16.35 – 17.00: The role of rFVIIIFc in immune tolerance, Stefan Lethagen, Sobi

Moderators: Robert Ariens (United Kingdom) and Lucas Di Meglio (France)

15.45 – 16.10: Role of clot properties in thrombosis and thromboembolism, Robert Ariens, United Kingdom

16.10 – 16.35: The impact of clot composition on mechanical thrombectomy, Mahmood Mirza, Cerenovus, Johnson & Johnson

16.35 – 17.00: The story of mrclean: clot removal in acute ischemic stroke, Robert-Jan Goldhoorn, The Netherlands

Moderators: Tilman Hackeng (The Netherlands) and Bérangère Joly (France)

15.45 – 16.10: Factor XIa assays, Henri Spronk, The Netherlands

16.10 – 16.35: Impact of reduced FXIa activity on thrombosis and hemostasis, Stefan Heitmeier, Bayer

16.35 – 17.00: Factor XIa in vascular coagulation and inflammation, Philip Wenzel, Germany

Moderators: Frits Rosendaal (The Netherlands) and Lucia Stanciakova (Slovakia)

15.45 – 16.10: Quantitative targeted mass spectrometry for measurement of coagulation factors and other plasma proteins, Yassene Mohammed, Canada/The Netherlands

16.10 – 16.35: Metabolomics, Vinay Pawar, Metabolon

16.35 – 17.00: Application of metabolomics in studies of complex traits, Dennis Mook-Kanamori, The Netherlands

Download the poster overview here

Moderator: Banne Nemeth (The Netherlands)

• Never kill TFPI, Tilman Hackeng, The Netherlands
• Inflammation is the most important activator of clotting in vivo, Pablo García De Frutos, Spain
• Immediately stop all VKA treatment, Leon Schurgers, The Netherlands
• Thrombin Generation is useless for personal risk assessment, Henri Spronk, The Netherlands